Tag: Pfeiser

Opinions on $PFE and $ELY

PFE – Pfiser Inc, a global bio-pharmaceutical company, has been on a downtrend since November 2015. Analysts believe the stock is undervalued, especially post the announcement of FDA approval of the drug – Xeljanz XR (tofacitinib citrate)

PFE – Pfiser Inc
Fundamentals Previously closed at 30.01
Day’s high 30.08
Day’s low 29.51
P/E ratio 24.25
EPS 1.24

 

Analysts opinion PFE has a PEG ratio of 2.42, P/S of 3.79 and a P/B of 2.77. Currently, its forward P/E is 12.15, lower than the stocks in the SPX at 17.
Sentiments Xeljanz XR is the first and only oral treatment for RA (Rheumatoid arthritis), which is a chronic, inflammatory autoimmune disease that causes a range of symptoms, including pain and swelling in the joints, particularly those in the hands, feet and knees. This drug is approved in more than 45 countries in the world, and PFE has huge potential for the drug. According to statistics, 1.3 million Americans have RA, and out of every 100,000 people, 41 are diagonised with RA every year.
 Despite the announcement, the stock had lower sentiments yesterday. Analysts believe that eventually, the market will rise to take into consideration the increased potential of the firm due to FDA approval.
Revenue Prediction The estimize consensus EPS for Q1 2016 is $0.55 and the revenue for the same period is $12,064 million
Social Pulse The stock has 43% lower social chatter than usual.

Continue Reading…

$PFE and $DIS may have positive market sentiments in the near future

Let’s look at what analyst’s have to say about $PFE and $DIS-

PFE- Pfizer, Inc.
Analytics Previously closed at 30.17
Day’s high 30.34
Day’s low 29.81
P/E Ratio 22.6
EPS 1.33

 

Analysts opinion Analyst look into as bullish trend for the company’s stocks post  its recent acquisition of Treerly and its family of product from Sirio pharma.
Sentiments Earnings growth last year had been -16.32% when compared to this year of -3.38%. How ever the EPS projection is to increase by 0.51. Stock volume traded also had a fluctuation but has improved when compared to weeks trade.
The sentiments for the pharmaceutical major had taken a dip post its EPS projection, however the earning growth for the next 5 years is expected to increase by 6.80%
More Bullish as the pharmaceutical industry is looking for growth in the coming quarters
Revenue prediction Pfizer Inc. had 3rd quarter 2015 revenues of $12.09 billion, the average growth rate is expected to be around 0.15%, however with the slow movement of API products the annual revenue might take a hit by  -5.70%
Social pulse 16% lower than normal, due to lesser message volumes and on sentiment pulse.

 

Continue Reading…